A Phase I Clinical Study of Safety, Tolerability, Pharmacokinetic/pharmacodynamic Characteristics and Initial Efficacy of LNF2007 Monotherapy in Patients with Advanced Solid Tumors
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs LNF 2007 (Primary)
- Indications Cholangiocarcinoma; Gastric cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Shandong New Time Pharmaceutical Co LTD
- 07 Jan 2025 New trial record